| Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response : genetic, epigenetic and clinical analyses | Molecular psychiatry |  | | 2025 | 8 | 169 |
|
| Influence of CYP2D6 Genotypes and Phenotypes on the Plasma Levels and Clinical Response to Aripiprazole | Schizophrenia bulletin | | | 2025 | 12 | 146 |
|
| Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis : a 3-year follow-up longitudinal study | Molecular psychiatry | | | 2024 | 60 | 322 |
|
| Infant exposure to Fluvoxamine through placenta and human milk : a case series - A contribution from the ConcePTION project | Frontiers in psychiatry | | | 2023 | 82 | 93 |
|
| Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium | Schizophrenia research | | | 2022 | 45 | 142 |
|
| Body Composition Assessment by Dual-Energy X-Ray Absorptiometry: A Useful Tool for the Diagnosis of Lipedema | Obesity facts | | | 2022 | 193 | 714 |
|
| Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia | JAMA psychiatry | | | 2022 | 36 | 152 |
|
| Case Report: Opioid Use Disorder Associated With Low/Moderate Dose of Loperamide in an Intellectual Disability Patient With CYP3A and P-Glycoprotein Reduced Activity | Frontiers in psychiatry | | | 2022 | 110 | 140 |
|
| Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study | Pharmacopsychiatry | | | 2021 | 213 | 12,806 |
|
| Bioavailability of Vortioxetine After a Roux-en-Y Gastric Bypass | Obesity Surgery |  | | 2020 | 270 | 1 |
|
| A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk | British Journal of Clinical Pharmacology | | | 2020 | 447 | 2 |
|
| Genetic and clinic predictors of new onset diabetes mellitus after transplantation | The Pharmacogenomics Journal | | | 2019 | 371 | 0 |
|
| Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients | Clinical epigenetics | | | 2019 | 1 | 0 |
|
| Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients | American Journal of Transplantation | | | 2019 | 456 | 0 |
|
| Associations of Urinary Caffeine and Caffeine Metabolites With Arterial Stiffness in a Large Population-Based Study | Mayo Clinic Proceedings | | | 2018 | 486 | 1 |
|
| Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances | Frontiers in Psychiatry | | | 2018 | 466 | 314 |
|
| N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis | Schizophrenia bulletin | | | 2018 | 100 | 36 |
|
| CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation | Pharmacogenomics journal | | | 2017 | 709 | 0 |
|
| Association of genetic risk scores with body mass index in Swiss psychiatric cohorts | Pharmacogenetics and genomics | | | 2016 | 573 | 0 |
|
| Bon usage des antidépresseurs ISRS durant la grossesse – le défi de l'évaluation de la balance bénéfice-risque | Revue médicale suisse | | | 2016 | 695 | 5 |
|
| Association of PCK1 with Body Mass Index and Other Metabolic Features in Patients With Psychotropic Treatments | Journal of clinical psychopharmacology | | | 2015 | 606 | 1 |
|
| Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments | Pharmacogenetics and genomics | | | 2015 | 668 | 0 |
|
| Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolite excretions | Hypertension | | | 2015 | 602 | 1 |
|
| Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression | PloS one | | | 2015 | 619 | 256 |
|
| Blood pressure in relation to coffee and caffeine consumption | Current hypertension reports | | | 2014 | 608 | 1 |
|
| Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance | British journal of clinical pharmacology | | | 2014 | 601 | 0 |
|
| Free and total plasma levels of lopinavir during pregnancy, at delivery and postpartum: implications for dosage adjustments in pregnant women | Antiviral therapy | | | 2013 | 607 | 0 |
|
| Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population | JAMA psychiatry | | | 2013 | 689 | 0 |
|
| Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension | Human molecular genetics | | | 2012 | 856 | 2 |
|
| Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring | Journal of chromatography. B | | | 2011 | 773 | 2 |
|
| The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution | Expert opinion on drug metabolism & toxicology | | | 2010 | 630 | 0 |
|
| The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone | British journal of pharmacology | | | 2010 | 881 | 2 |
|
| Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety | British journal of pharmacology | | | 2010 | 659 | 1 |
|
| Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study | European journal of clinical pharmacology | | | 2009 | 728 | 366 |
|
| Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS | Journal of pharmaceutical and biomedical analysis | | | 2009 | 711 | 0 |
|
| Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples | Journal of chromatography. B | | | 2009 | 638 | 0 |
|
| Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals | Clinical pharmacology and therapeutics | | | 2009 | 681 | 0 |
|
| Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizer: Evidence of a safer cardiac profile of (R)-methadone | Pharmacopsychiatry | | | 2008 | 682 | 0 |
|
| CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response | Therapeutic drug monitoring | | | 2008 | 799 | 0 |
|
| Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit | European journal of medical research | | | 2008 | 496 | 0 |
|
| Follow-up of the metabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives | Revue médicale suisse | | | 2008 | 784 | 500 |
|
